Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to identify the maximum tolerated dose and dose-limiting side
effects of LCL161 in combination with gemcitabine and nab-paclitaxel and to provide safety
data in patients with measurable metastatic pancreatic cancer.